anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To evaluate the effect of a new strategy of transperineal anastomotic urethroplasty (TAU) with proximal transection in treating pelvic fracture urethral injury (PFUI) associated with urethrorectal fistula (URF).
PATIENTS AND METHODS: A retrospective review of all patients treated by TAU with proximal transection and fistula repair for PFUI associated with URF was performed between August 2013 and July 2022. Information on demographics, peri-operative variables, and postoperative follow-up outcomes was collected. Successful surgery was defined as restoration of a uniform urethral calibre using flexible cystoscopy (third postoperative month) without strictures or leakage, with no further interventions required. Functional outcomes, including erectile function (assessed using the five-item International Index of Erectile Function) and urinary continence, were assessed.
RESULTS: Forty patients diagnosed with PFUI associated with URF and treated by TAU with proximal transection and rectal fistula repair were enrolled. Six patients (15.0%) had a history of failed urethral reconstruction. The mean stenosis length and fistula diameter were 2.9 cm and 1.2 cm, respectively. All patients underwent faecal diversion before urethroplasty. After a median (range) follow-up of 45 (3-115) months, the final success rate was 90.0% (36/40). Postoperative complications included haematoma in three patients, epididymo-orchitis in three, wound infection in one, wound bleeding in one, delayed wound healing in three, and wound numbness in three. The overall incidence of postoperative erectile dysfunction reached 75.0%, with a median (range) score of 9 (0-19). Normal continence was achieved in 31 patients (77.5%). Occasional incontinence without the need for urinal pads occurred in eight patients, whereas one patient required urinal pads.
CONCLUSIONS: Transperineal anastomotic urethroplasty with proximal transection is a precise and effective surgical strategy for treating PFUI associated with URF. This strategy ensures a high success rate and improves surgical efficiency.
Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
The present invention relates to an improved child resistant sachet construction, suitable for holding a medicinal product, especially a flavored product. The sachet is a three seal sachet, or stick pack, made from a laminate sheet, the sachet having a fin seal along a longitudinal axis and transverse fin seals at each end. The laminate sheet is tough enough to resist tearing unless a notch is provided with which to initiate a tear. A fold line extends across a corner of the sachet and through the fin seal, a notch extending through the sachet in a transverse seal area and perpendicular to the fold line such that when the sachet is folded a cut is revealed that allows the user to initiate a tear across the pack opening up a pouring spout for dispensing the medicinal product. In an alternative aspect of the invention the laminate sheet is provided with an acrylonitrile methyl acrylate copolymer resin on the sheet face which forms the inside of the sachet. This layer provides improved retention of flavor while still allowing the sachet to be readily torn once a tear has been initiated.
The present invention belongs to the technical field of traditional Chinese medicines, which relates to Chinese medicinal powder with earthworm and medicated leaven for treating gastric diseases. The present invention is suitable for curing stomach cold, gastric ulcer, antral gastritis, duodenal bulbar ulcer and stomach spasm, and is characterized in that the present invention is composed of medicines of 8 to 12g of earthworm, 12 to 20g of six leaven, 0.5 to 1g of alum, 1 to 2g of haw and 5 to 10g of humus flava usta. The medicines are processed, mixed and pulverized to a powder shape, and is sieved, the granularity is 180 mesh, and the powder with earthworm and medicated leaven is made. The present invention can be effectively used for curing diseases of stomach cold, gastric ulcer, antral gastritis, duodenal bulbar ulcer, gastrospasm, etc. through clinical application. The present invention is clinically applied at present, and is used for curing patients of more than 2000 examples. The total effective rate is more than 98%, and the cure rate is more than 90% through clinical observation. The present invention has the advantages of short course of treatment, good curative effect, high cure rate and no toxic side effect.
Buzzy® was placed on the injection site and cold application and vibration were turned on 60 s before the procedure. Then, the nurse moved Buzzy® about 3-5 cm above the injection site. The procedure was performed with buzzy®. The Buzzy® intervention and phlebotomy were terminated at the same time.
Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS \<50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
BACKGROUND & AIMS: Complications after laparoscopic liver resection (LLR) are important factors affecting the prognosis of patients, especially for complex hepatobiliary diseases. The present study aimed to evaluate the value of a three-dimensional (3D) printed dry-laboratory model in the precise planning of LLR for complex hepatobiliary diseases.
METHODS: Patients with complex hepatobiliary diseases who underwent LLR were preoperatively enrolled, and divided into two groups according to whether using a 3D-printed dry-laboratory model (3D vs. control group). Clinical variables were assessed and complications were graded by the Clavien-Dindo classification. The Comprehensive Complication Index (CCI) scores were calculated and compared for each patient. Multivariable analysis was performed to determine the risk factors of postoperative complications.
RESULTS: Sixty-two patients with complex hepatobiliary diseases underwent the precise planning of LLR. Among them, thirty-one patients acquired the guidance of a 3D-printed dry-laboratory model, and others were only guided by traditional enhanced CT or MRI. The results showed no significant differences between the two groups in baseline characters. However, compared to the control group, the 3D group had a lower incidence of intraoperative blood loss, as well as postoperative 30-day and major complications, especially bile leakage (all P < 0.05). The median score on the CCI was 20.9 (range 8.7-51.8) in the control group and 8.7 (range 8.7-43.4) in the 3D group (mean difference, -12.2, P = 0.004). Multivariable analysis showed the 3D model was an independent protective factor in decreasing postoperative complications. Subgroup analysis also showed that a 3D model could decrease postoperative complications, especially for bile leakage in patients with intrahepatic cholelithiasis.
CONCLUSION: The 3D-printed models can help reduce postoperative complications. The 3D-printed models should be recommended for patients with complex hepatobiliary diseases undergoing precise planning LLR.
BACKGROUND: Prior studies have shown an increased risk of complications and flap loss with the use of vein grafts in microsurgery. We hypothesize that indication for use of a vein graft can affect flap complications and loss rates.
METHODS: We performed a retrospective review of all patients at our institution from 2010 to 2020 who underwent free flap reconstruction and required use of a vein graft. Indications for vein grafting included: salvage of flap during primary operation after microvascular compromise, augmentation of flow during primary operation, lengthening of the flap pedicle during the primary operation, and salvage of the flap during a secondary salvage operation after microvascular compromise.
RESULTS: A total of 79 patients met the study inclusion criteria. There were significant differences among the vein graft indication groups and the following: area of reconstruction (p = 0.002), vein graft length (p = 0.018), vessels grafted (p = 0.001), vein graft donor site (p = 0.011), and total flap loss (p = 0.047). Of the four indications for vein grafting, salvage of the flap during secondary salvage operation after microvascular compromise had the highest rate of total flap loss (26.7%). There were no significant associations between other flap complications and vein graft indications.
CONCLUSION: Vein graft use in the primary reconstructive setting is efficacious, with low risk of thrombosis. Use in secondary procedures, however, is associated with higher rates of total flap loss, likely due to the thrombotic process, which was initiated prior to the use of the graft resulting in the salvage procedure and not secondary to the graft itself.
The present invention relates to novel oil-in-water nanoemulsions. The oily phase comprises a triglyceride oil and/or petrolatum and C 8 ‑C 18 Oils of fatty acids; the aqueous phase contains a specific N-acyl derivative having a counter ion of a specific amino acid salt as an emulsifier, glycerol, and water. When (i) a defined ratio of glycerol to water; (ii) (ii) specific counter ion of amino acid surfactant and (iii) fatty acid in oil phase, the nanoemulsion is processed in a one-step process, producing droplets of size 20-400 nm. In one embodiment, droplets of size 20-400nm can be prepared using a rotor-stator device (in a one-step process) and in the absence of a pressure-based homogenizer. This saves energy and cost. Compositions prepared according to the method are also contemplated.
The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include surgical hand disinfection and the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a topical broad–spectrum microbicide should be given prior to the injection.

Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.

Following intravitreal injection, patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis or retinal detachment (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay [see Patient Counseling Information (17)].

Each vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field (including a new syringe, gloves, drapes, eyelid speculum, filter and injection needles) should be changed before EYLEA HD is administered to the other eye.

After injection, discard any unused product or waste material in accordance with local regulations.
<P>PROBLEM TO BE SOLVED: To provide a medical diagnostic device capable of securing the security of medical data without damaging the operability of the medical image diagnostic device.  <P>SOLUTION: In the case of authenticating fingerprints by using a fingerprint sensor 71b, by combining the fingerprint sensor 71b with a reset switch 71a for resetting testee body information, the reset of the testee body information and authentication can be performed by one operation. That is, in the case of executing an examination to a new testee body, since the reset switch 71a for resetting the testee body information is surely pressed, the fingerprint is authenticated surely by the fingerprint sensor 71b. Thus, the need of placing a finger on the fingerprint sensor 71b and authenticating it separately other than the operation of pressing the switch for resetting the testee body information is eliminated. While securing the operability in such a manner, the security is secured as well.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
PF-07220060 given as tablet by mouth twice a day for 14 days. Letrozole given as tablet by mouth once a day for 14 days.
The aim of this study is to investigate circadian rhythms in independently living adults with obesity and mental disease, exploring the interplay between biological markers and lifestyle factors. Eighty participants divided equally into four groups; (i) people with obesity and schizophrenia; (ii) people with obesity and bipolar disorder; (iii) people with obesity without mental disease or sleep disorders, and (iv) people without obesity, mental disease or sleep disorders. Over two consecutive days, participants engage in repeated self-sampling of hair follicle and saliva; concurrently, data is collected on diet, body temperature, light exposure, sleep parameters, and physical activity by accelerometry. Hair follicles are analyzed for circadian gene expression, saliva samples for cortisol and melatonin concentrations. Circadian rhythms are investigated by cosinor analysis. The study employs a participant-tailored sampling schedule to minimize disruptions to daily routine and enhance ecological validity. The methodology aims to provide a comprehensive insight into the factors contributing to circadian disruptions in people with obesity, bipolar disorder and schizophrenia, potentially informing strategies for future management and mitigation. Trial registration: (ClinicalTrials.gov Identifier: NCT05413486).
All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as blood gases(ScvO2) from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
A number of published studies in anesthesia have demonstrated that certain patient factors may impact patient perioperative outcomes. Factors such as age, gender, cardiac function, and hemodynamic status all have been shown to be predictive indicators. The goal of the present study is to evaluate these factors with the effectiveness of the Goal Directed Fluid Management training on patient outcomes after major surgeries and document the final perioperative outcomes.

This is an observational study in which patients' de-identified clinical information will be extracted from the University of California, Irvine Medical Center electronic medical record system to evaluate whether there has been a change in patients' outcomes after the Goal-Directed Fluid Management training curriculum was implemented. We will extract data from both before and after the training took place-- the time-frame is from June 15, 2011 to September 15, 2013. Specifically we will be looking at 30 day re-admission and 90 day mortality following surgery. There are no study procedures or use of biological material. Patient identifies are utilized in the secure database as this is utilized for clinical management. When the data is extracted from the database for research purposes the patient identifiers will be removed and no patient identifiers will be included in the information during statistical analysis or subsequent reporting. For publication, only aggregate data is utilized. No identifiable patient information will be released at any time.

Statistical considerations may include: Sample Size Considerations, Predictors, Covariates/Cofounders, Statistical Goal(s), Statistical Approach, and Secondary Analysis. Specifically, statistical analysis will be performed using computerized software (SPSS for Windows version 12.0). For data that was non-normally distributed a Mann Mann-Whitney test will be used and normally distributed data will be compared using the Student T-test. Ordinal and nominal data will compared using Chi-Square analysis. A p value smaller or equal to 0.05 will be considered significant. These statistical considerations will aid in supporting the study's hypothesis for patient outcomes improvement with Early Goal Directed Fluid Management training.
Multiple Channel Exposure Therapy -Veterans (MCET-V) is a 12-session cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks. It is an integrated treatment designed to target panic and PTSD symptoms simultaneously.
PROBLEM TO BE SOLVED: To obtain a spray agent for pruritic dermatosis capable of exhibiting a rapid antipruritic effect and antiphlogistic effect, etc. SOLUTION: This spray agent for pruritic dermatosis contains an antipruritic agent, a local anesthetic agent, a germicide, an astringent agent and a moisture absorbent as active ingredients. The amounts of the contained ingredients based on 100 pts.wt. of ingredients other than a propellant are 0.5-5 pts.wt. of the antipruritic agent, 0.5-10 pts.wt. of the local anesthetic agent, 0.05-1 pt.wt. of the germicide, 1-20 pts.wt. of the astringent agent and 30-95 pts.wt. of the moisture absorbent.
First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
INTRODUCTION: surgical site infection is associated with longer postoperative hospital stays. We explored factors associated with longer postoperative hospital stays among patients in the surgical ward of a primary rural hospital in Ethiopia, where laboratory facilities for microbiological confirmation of surgical site infections were not available.
METHODS: an observational study was performed for patients ≥ 18 years of age who underwent elective or emergency surgery from 22nd June 2017 to 19th July 2018. Data were taken from paper-based medical records and patient interviews. The primary outcome was postoperative length of hospital stay. Data were analyzed by multivariable linear regression using Stata software, version 13.
RESULTS: seventy-five patients were enrolled, sociodemographic data was obtained from 14 of these patients by interview, and 44 patients had complete outcome and covariate data and were included in regression analysis. Median length of preoperative hospital stay was 3.0 (interquartile range 2.0) days. Postoperative length of hospital stay was longer by 3.8 days (95% confidence interval (CI) 1.05-6.55; p=0.008), 4.7 days (95% CI 1.64-7.66; p=0.004), and 5.9 days (95% CI 2.70-9.02; p=0.001), for patients 35-54 years, 55-64 years and the 65+ years respectively, compared to patients who were 18-34 years of age. Patients who received preoperative antibiotics stayed 5.3 days longer (95% CI 1.67-8.87; p=0.005) compared to those who were not given preoperative antibiotics.
CONCLUSION: age and improper use of preoperative antibiotics compound the risk for postoperative length of stay. Infection prevention protocols, including staff training, and surveillance for surgical site infections are critical for improving hospital outcomes.
A diagnostic preparation consists of an emulsion of a solution of a film-forming substance in a volatile solvent with a non-volatile liquid vehicle substance which is insoluble in the aforesaid solution and contains a diagnostic allergenic or antigenic substance. Preferably the solution of film-forming substance is the continuous phase and the liquid vehicle for the diagnostic substance is hygroscopic.  A wetting agent may be added to promote stability of the emulsion.  Specified film-forming substances are pyroxylin, polyvinyl chloride-vinyl acetate copolymer, the acetal from polyvinyl alcohol and butraldehyde, cellulose acetate butyrate, ethyl cellulose and resins.  These may be dissolved in volatile solvents such as ether-alcohol, ethyl acetate, dimethyl ketone, cyclohexanol, toluene, benzene, ethylene dichloride and nitro-ethane.  Specified diagnostic substances are tuberculin, navy bean, peanut mustard, whitefish and horse serum allegens dissolved in glycerine-water, propylene glycol-water, sorbitol-water.  A small proportion of a dioctyl ester of sodium sulphosuccinic acid, isopropyl napthalene sodiumsulphonate, a sodium salt of a higher secondary alkyl sulphate, or a petroleum sulphonate may be added to the emulsion. The above preparations when applied to the skin dry to form a film enclosing droplets of the non-volatile liquid containing the diagnostic substance.
Using a protein associated with myc (PAM) (I) or its functional fragments or derivatives for the preparation of pharmaceutical compounds, for modulation of pain and for identifying compounds that modulate pain, is new. An independent claim is also included for PAM or its functional fragment for the use as medicament for the prevention or treatment of pain. ACTIVITY : Analgesic. MECHANISM OF ACTION : Inhibits adenylyl cyclase activity (claimed). In vitro analysis of the activity of protein associated with myc (PAM) in inhibiting adenylyl cyclase activity was carried out as follows. The sense or antisense oligonucleotides of PAM were infused through a catheter at a flow rate of 0.05-0.1 mu l/minute for 100 hours using a microinfusion pump, into rats. Within 15 minutes after stopping the infusion, the formalin test was performed. For induction of an inflammation, Zymosan A was injected subcutaneously. Rats were killed by cardiac puncture under deep isoflurane anesthesia 24-96 hours after Zymosan injection. The lumbar spinal cord and dorsal root ganglia were excised, and subjected to analysis. The result indicated an inhibition of adenylyl cyclase activity in the spinal cord lysates of the sense strand treated rats, and an increase in adenylyl cyclase activity in the antisense treated rats.